Cargando…

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism of action in vivo is incompletely understood. Here, we define correlates of protection of neutralizing human monoclonal antibod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winkler, Emma S., Gilchuk, Pavlo, Yu, Jinsheng, Bailey, Adam L., Chen, Rita E., Chong, Zhenlu, Zost, Seth J., Jang, Hyesun, Huang, Ying, Allen, James D., Case, James Brett, Sutton, Rachel E., Carnahan, Robert H., Darling, Tamarand L., Boon, Adrianus C.M., Mack, Matthias, Head, Richard D., Ross, Ted M., Crowe, James E., Diamond, Michael S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879018/ https://www.ncbi.nlm.nih.gov/pubmed/33691139 http://dx.doi.org/10.1016/j.cell.2021.02.026

Ejemplares similares

Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape
por: Suryadevara, Naveenchandra, et al.
Publicado: (2022)

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
por: Diamond, Michael, et al.
Publicado: (2021)

Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development
por: Murin, Charles D., et al.
Publicado: (2022)

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
por: Suryadevara, Naveenchandra, et al.
Publicado: (2021)

A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein
por: Mousa, Jarrod J., et al.
Publicado: (2017)

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
por: Chen, Elaine C., et al.
Publicado: (2021)

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
por: VanBlargan, Laura A., et al.
Publicado: (2021)

A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters
por: Bricker, Traci L., et al.
Publicado: (2021)

Standardized two-step testing of antibody activity in COVID-19 convalescent plasma
por: Gilchuk, Pavlo, et al.
Publicado: (2021)

Antiviral protection by antibodies targeting the glycan cap of Ebola virus glycoprotein requires activation of the complement system
por: Bukreyev, Alexander, et al.
Publicado: (2023)

A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters
por: Ying, Baoling, et al.
Publicado: (2023)

Nasally-delivered interferon-λ protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including Omicron
por: Chong, Zhenlu, et al.
Publicado: (2022)

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
por: Dong, Jinhui, et al.
Publicado: (2021)

Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters
por: Boon, Adrianus C. M., et al.
Publicado: (2022)

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
por: Greaney, Allison J., et al.
Publicado: (2020)

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
por: Greaney, Allison J., et al.
Publicado: (2021)

A budding new approach strengthens an important message
por: Zost, Seth J., et al.
Publicado: (2023)

An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo
por: Tsuji, Moriya, et al.
Publicado: (2023)

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro
por: Swaim, Caleb D., et al.
Publicado: (2021)

Human antibody recognition of H7N9 influenza virus HA following natural infection
por: Gilchuk, Iuliia M., et al.
Publicado: (2021)

Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes
por: Chen, Elaine C., et al.
Publicado: (2023)

Potently neutralizing and protective human antibodies against SARS-CoV-2
por: Zost, Seth J., et al.
Publicado: (2020)

Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron
por: Chong, Zhenlu, et al.
Publicado: (2022)

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
por: Diamond, Michael, et al.
Publicado: (2021)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura, et al.
Publicado: (2021)

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities
por: Swaim, Caleb D., et al.
Publicado: (2020)

Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
por: Shiakolas, Andrea R., et al.
Publicado: (2021)

On the road to ending the COVID-19 pandemic: Are we there yet?
por: Case, James Brett, et al.
Publicado: (2021)

Intracellular Crosslinking of Filoviral Nucleoproteins with Xintrabodies Restricts Viral Packaging
por: Darling, Tamarand Lee, et al.
Publicado: (2017)

Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap
por: Ilinykh, Philipp A., et al.
Publicado: (2018)

Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk
por: King, Liam B., et al.
Publicado: (2019)

A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants
por: Schmitz, Aaron J., et al.
Publicado: (2021)

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
por: Darling, Tamarand L., et al.
Publicado: (2022)

Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
por: Su, Wen, et al.
Publicado: (2021)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura A., et al.
Publicado: (2022)

A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
por: Cobb, Ronald R., et al.
Publicado: (2022)

Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease
por: Powell, Laura A., et al.
Publicado: (2020)

mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19
por: Kackos, Christina M., et al.
Publicado: (2023)

A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA
por: Bangaru, Sandhya, et al.
Publicado: (2018)

The highly conserved stem-loop II motif is dispensable for SARS-CoV-2
por: Jiang, Hongbing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c97ap34ek47c2rim00n0a1vpe9